This week we celebrated the grand opening of our new office in Dublin. The international headquarters will continue to play a key role in PTC’s expanding commercial portfolio and pipeline, ensuring PTC’s innovative medicines reach more rare disease patients worldwide.
PTC Therapeutics, Inc.
Biotechnology Research
We're committed to a single purpose: Extending life’s moments for patients with rare diseases and their loved ones.
About us
PTC is a patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for children and adults living with rare and serious disease.
- Website
-
https://ptcbio.com/
External link for PTC Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Type
- Public Company
- Founded
- 1998
- Specialties
- Orphan and Ultra-orphan Disorders, Oncology, and Anti-infectives
Locations
-
Primary
-
500 Warren Corporate Center Drive
Warren, NJ 07059, US
Employees at PTC Therapeutics, Inc.
Updates
-
We were thrilled to sponsor and participate in this year's Help 4 HD Symposium in Arlington, Virginia last weekend. Meeting and connecting with the #HD community remains a key priority to gain valuable insights and hear directly about the experiences of people living with #HuntingtonsDisease and their families. Congrats to our team on a successful event! Anne Bruns, Mary Frances Harmon, Karen Galambos, Ryan Miller
-
Today we're thrilled to share several positive updates on the vatiquinone Friedreich ataxia (FA) program. The pre-specified endpoint for two different #FA long-term extension studies was met, with highly statistically significant evidence of durable treatment benefit on disease progression. In addition, PTC recently aligned with FDA on key aspects of the planned NDA submission for vatiquinone. Learn more: https://bit.ly/4eBjRzA
-
We are looking forward to participating in the upcoming 29th Annual Congress of the World Muscle Society from October 8-12 in Prague. Learn more about the data we’ll be sharing through our poster presentations below and be sure to stop by Booth #3 to meet the team! We look forward to seeing you there. #WMS2024 #Duchenne #DMD
-
When it comes to rare diseases, every story is a journey that deserves to be told. At PTC Therapeutics we believe that empowering the #raredisease community and elevating their voices is critical to raising awareness about these conditions around the world. We’re proud to introduce the Rare Journeys Hub: a centralized home where you can discover stories from people in the rare disease community. Kevin, who used his passion for storytelling to produce a documentary about life with PKU and take ownership of his rare disease story. Kelly, who went to school to become a nurse after her daughter Jillian was diagnosed with AADC deficiency, so that she could properly support and care for her. Jenna, who learned at just 18 years old that she was living with Huntington's disease (HD), felt lost and alone as she tried to understand her condition until she found the right support and soon became a leading advocate for the HD community. We invite you to click through the #RareJourneys hub and learn more about their stories along with many more of the adults and children living with rare conditions. 🔗: https://bit.ly/3zMXVm8 #AADCdeficiency #PKU #FriedreichAtaxia #FA #Duchenne #DMD #Huntingtonsdisease #HD #SMA
-
PTC employees worldwide are proudly celebrating our #PTCEurope10 milestone! Cross-functional teams from supply chain, medical, legal and our CIS regional team have all played a crucial role in PTC’s regional and global success throughout the last decade. Thank you, team! #OnePTC Learn more: https://bit.ly/4dnvwRW
-
We're thrilled to announce today that the FDA has accepted our filing for the New Drug Application (NDA) of sepiapterin for treating pediatric and adult patients living with phenylketonuria (PKU). Learn more: https://bit.ly/47PjzTe
-
We are deeply committed to patients living with rare diseases who have little to no treatment options, and this passion fuels and inspires us. This weekend our team will be attending the International Congress of Parkinson’s Disease and Movement Disorders in Philadelphia to meet with leading experts about current research and approaches for the diagnosis and treatment of movement disorders including #AADC deficiency and other neurologic conditions. Visit us at booth #212 to learn more. #MDScongress
-
We're honored to receive the Brandon Hall Group's Excellence Award this year, winning gold for Best Learning Strategy! This award celebrates our strengths-based learning program's successful impact on PTC, as we remain committed to supporting our employees individually, as leaders and as team members to be the best they can be. The Excellence Award recognizes organizations for successfully implementing programs, strategies, modalities, processes, systems, and tools that achieve measurable results. Congratulations on this incredible #OnePTC effort to help earn this well-deserved award! 🎉
-
At PTC, we’re proud to be pushing the boundaries of innovation by leveraging cutting-edge science to address serious unmet medical needs. Discover how our #ferroptosis and inflammation platform is opening new approaches to fight neurodegenerative diseases. This new peer-reviewed publication highlights recent data from our preclinical #Parkinsons disease program in which we are targeting the ferroptosis pathway to simultaneously address multiple aspects of PD pathology. Read more: https://bit.ly/3ZEZo8j
Affiliated pages
Similar pages
Browse jobs
Stock
PTCT
NASDAQ
20 minutes delay
$39.00
0.51 (1.325%)
- Open
- 38.48
- Low
- 38.29
- High
- 39.22
Data from Refinitiv
See more info on